Please login to the form below

Not currently logged in
Email:
Password:

Kantar’s Gracie van Kemenade appointed quantitative director at Insight Research Group

Paul O’Meara also joins as regional head of syndicated studies

Gracie van Kemenade has left Kantar Health to join Insight Research Group as quantative director.

She is joined at the market research company by fellow new recruit Paul O'Meara, who has been appointed regional head of syndicated studies.

Van Kemenade was previously global account lead for major pharmaceutical companies at Kantar, and will work across the whole research team in her new role at Insight.

Her main focus will be to work with Insight's existing quantitative research team and apply her experience in the development of new proprietary quantitative research methodologies.

In addition, van Kemenade has experience in market landscape, target product profiling, patient record studies, launch tracking and brand equity research.

Grace van Kemenade - Insight Research GroupPaul O'Meara - Insight Research Group
Gracie van Kemenade and Paul O'Meara

O'Meara was most recently at Ipsos Healthcare where he was head of syndicated studies for the Asia-Pacific region.

Nicola Cowland, joint CEO at Insight Research Group, said of O'Meara and van Kemenade: “Their recruitment is the latest step in bolstering Insight's quantitative research capabilities, developing innovative and valuable new research offerings and affirming our presence as a leading global player in quantitative, qualitative and digital market research in the healthcare sector.”

21st August 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics